Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, researchers detailed the clinical management and positive outcome of a 62-year-old woman with catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, highlighting the potential effectiveness of Eculizumab in achieving disease remission and maintaining stability over 18 months.

This letter to the editor discusses the natural course of epidermolysis bullosa simplex with mottled pigmentation in a Japanese family but does not present new clinical results.

This study found that parental reports of neuro-psychiatric disorders were higher in children exposed to maternal anti-Ro antibodies, yet these differences compared to controls were not statistically significant.

This study suggests that the presence and arrangement of plasmacytoid dendritic cells can help distinguish chronic cutaneous lupus erythematosus from other types of scarring alopecia.

The review says skin conditions with sterile pustules need more research for better treatments.

This case report describes a 42-year-old woman with rheumatoid arthritis who developed extensive impetiginized pityriasis amiantacea potentially linked to her anti-TNF-α therapy with golimumab. Discontinuing the drug and other treatments led to significant clinical improvement within a month.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

This case study describes a previously unknown association of the PIBIDS complex with autoimmune thyroiditis and autoimmune hemolytic anemia in a five-year-old Indian child.

This article reviews strategies for serological testing in diagnosing ILD linked to systemic rheumatic diseases and introduces a potential diagnostic algorithm for pulmonologists, while noting further validation is needed.

A 5-year-old girl with a rare skin disorder was effectively treated with skin creams instead of oral medication.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that the new cocrystal formulation KET-PABA improved the antimycotic efficiency of ketoconazole and induced an anti-inflammatory response without causing skin sensitization in mice.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

This study described the clinical characteristics of keratosis pilaris atrophicans faciei in 14 patients, noting that earlier diagnosis may enable more targeted treatment options.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

KAP8.1 protein is crucial for hair structure and interacts with keratin 85.

This study found that most pathogenic HR mutants associated with atrichia with papular lesions had abolished corepressor activity due to defective interactions with histone deacetylases.

In this study, the researchers cloned and analyzed the CRABP I gene in Inner Mongolian cashmere goats, finding its highest mRNA expression at 90 days in embryo skin compared to later stages.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

This study found that a history of smoking significantly predicted a more refractory course of palmoplantar pustulosis, with associated comorbidities often including hypertension, type 2 diabetes mellitus, and thyroid diseases.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This case study describes a patient with myasthenia gravis associated with pityriasis rubra pilaris, suggesting a rare coexistence of these conditions.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This study observed that PD-1+CXCR5-CD4+T peripheral helper cells are significantly elevated in patients with systemic lupus erythematosus and are correlated with disease activity indicators, suggesting their potential role in lupus pathogenesis.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

This study found that women with polycystic ovary syndrome have a higher prevalence of autoimmune thyroid disease compared to those without the condition, highlighting the importance of screening for thyroid issues in this population.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This case report details the development of a psoriasiform rash and inflammatory alopecia in a 29-year-old man with severe atopic dermatitis following dupilumab treatment. The authors observed hair regrowth and eczema control after discontinuing dupilumab and beginning treatment with abrocitinib.

This meeting abstract volume for the Society for Pediatric Dermatology reports no new clinical results.